Lack of Impact of Expansion Size From Gross Tumor Volume to Planning Target Volume on Control Rates and Patterns of Recurrence in Fractionated Radiotherapy for WHO Grade 1 Meningiomas.

IF 1.6 4区 医学 Q4 ONCOLOGY
Christopher R Weil, Calvin B Rock, Vikren Sarkar, Nicholas Gravbrot, Felicia H Lew, Christian B Rock, Lindsay M Burt, Cristina M DeCesaris, Randy L Jensen, Dennis C Shrieve, Donald M Cannon
{"title":"Lack of Impact of Expansion Size From Gross Tumor Volume to Planning Target Volume on Control Rates and Patterns of Recurrence in Fractionated Radiotherapy for WHO Grade 1 Meningiomas.","authors":"Christopher R Weil, Calvin B Rock, Vikren Sarkar, Nicholas Gravbrot, Felicia H Lew, Christian B Rock, Lindsay M Burt, Cristina M DeCesaris, Randy L Jensen, Dennis C Shrieve, Donald M Cannon","doi":"10.1097/COC.0000000000001193","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>For single-fraction stereotactic radiosurgery (SRS) for WHO grade I meningiomas, no-GTV or minimal-GTV to PTV margin is an accepted practice. We evaluated whether there is a control difference based on GTV to PTV expansion size for fractionated RT.</p><p><strong>Methods: </strong>Eighty-seven patients with WHO grade 1 meningioma were identified from an institutional database, treated with either conventional immobilization and radiation treatment delivery techniques (cRT) with 5 to 20 mm PTV expansions or fractionated stereotactic radiotherapy (fSRT) with ≤3 mm GTV to PTV expansions. Kaplan-Meier estimators were used for local failure-free survival (LFFS), marginal-failure-free survival (MFFS), and distant failure-free survival (DFFS) analysis.</p><p><strong>Results: </strong>The median follow-up duration was 9.0 years. Twenty-five patients (29%) received cRT and 62 patients (71%) received fSRT. The median dose was 54 Gray. There were 4 local (5%), 1 marginal (1%), and 1 distant failure (1%). The fSRT and cRT groups each had 2 local failures; 3/4 local failures occurred in areas near critical organs at risk. For cRT versus fSRT, 5-year and 10-year LFFS were 100% versus 98% (P=0.46) and 94% versus 96% (P=0.34), 5-year and 10-year MFFS were 100% versus 100% and 100% versus 92% (P=0.004), and 5-year and 10-year DFFS were 100% versus 98% at both time points (P=0.65 and P=0.67, respectively).</p><p><strong>Conclusions: </strong>In this patient cohort, there was no local control benefit for larger GTV-to-PTV expansions. For patients with tumors not eligible for SRS, fractionated stereotactic treatment workflow with ≤3 mm PTV expansions is an effective approach for WHO grade 1 meningiomas.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001193","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: For single-fraction stereotactic radiosurgery (SRS) for WHO grade I meningiomas, no-GTV or minimal-GTV to PTV margin is an accepted practice. We evaluated whether there is a control difference based on GTV to PTV expansion size for fractionated RT.

Methods: Eighty-seven patients with WHO grade 1 meningioma were identified from an institutional database, treated with either conventional immobilization and radiation treatment delivery techniques (cRT) with 5 to 20 mm PTV expansions or fractionated stereotactic radiotherapy (fSRT) with ≤3 mm GTV to PTV expansions. Kaplan-Meier estimators were used for local failure-free survival (LFFS), marginal-failure-free survival (MFFS), and distant failure-free survival (DFFS) analysis.

Results: The median follow-up duration was 9.0 years. Twenty-five patients (29%) received cRT and 62 patients (71%) received fSRT. The median dose was 54 Gray. There were 4 local (5%), 1 marginal (1%), and 1 distant failure (1%). The fSRT and cRT groups each had 2 local failures; 3/4 local failures occurred in areas near critical organs at risk. For cRT versus fSRT, 5-year and 10-year LFFS were 100% versus 98% (P=0.46) and 94% versus 96% (P=0.34), 5-year and 10-year MFFS were 100% versus 100% and 100% versus 92% (P=0.004), and 5-year and 10-year DFFS were 100% versus 98% at both time points (P=0.65 and P=0.67, respectively).

Conclusions: In this patient cohort, there was no local control benefit for larger GTV-to-PTV expansions. For patients with tumors not eligible for SRS, fractionated stereotactic treatment workflow with ≤3 mm PTV expansions is an effective approach for WHO grade 1 meningiomas.

WHO 1级脑膜瘤分级放疗中,从肿瘤总体积到计划靶体积的扩张大小对控制率和复发率缺乏影响。
目的:对于WHO一级脑膜瘤的单分数立体定向放射手术(SRS),无gtv或最小gtv到PTV边界是一种公认的做法。方法:87例WHO 1级脑膜瘤患者从一个机构数据库中被识别出来,接受常规固定和放射治疗输送技术(cRT)治疗,PTV扩张5 - 20mm,或分块立体定向放疗(fSRT)治疗,GTV至PTV扩张≤3mm。Kaplan-Meier估计用于局部无故障生存(LFFS)、边际无故障生存(MFFS)和远程无故障生存(DFFS)分析。结果:中位随访时间为9.0年。25例患者(29%)接受cRT, 62例患者(71%)接受fSRT。中位剂量为54格雷。局部失败4例(5%),边缘失败1例(1%),远处失败1例(1%)。fSRT组和cRT组各有2例局部失败;3/4的局部故障发生在有危险的关键器官附近。对于cRT和fSRT, 5年和10年LFFS分别为100%对98% (P=0.46)和94%对96% (P=0.34), 5年和10年MFFS分别为100%对100%和100%对92% (P=0.004), 5年和10年DFFS分别为100%对98% (P=0.65和P=0.67)。结论:在该患者队列中,更大的gtv - ptv扩张没有局部控制益处。对于不符合SRS条件的肿瘤患者,分级立体定向治疗流程与≤3mm PTV扩张是治疗WHO 1级脑膜瘤的有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
130
审稿时长
4-8 weeks
期刊介绍: ​​​​​​​American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信